AstraZeneca India has established a partnership with Alveofit, a SaaS-IoT enabled respiratory healthcare platform, to offer IoT enabled portable spirometers in hospitals across the nation through its A.Catalyst network.
This collaboration intends to include the most recent technological developments in detecting and managing lung disorders and associated noncommunicable diseases such as asthma, pulmonary fibrosis, and COPD.
As part of this collaboration with Alveofit, AstraZeneca will supply Alveofit IoT enabled handheld spirometers to clinics and last mile hospitals to enable point of care spirometry for optimal management of several lung associated noncommunicable diseases. This will allow patients to be tracked remotely and potentially conduct telespirometry with comprehensive care management solutions.
AstraZeneca’s A.Catalyst Network embodies the company’s dedication to harnessing the power of science to make health a reality for as many people, in as many countries, and in as many ways as possible.
As part of its collaboration with Alveofit, AstraZeneca has placed spirometers at select hospitals across the country. This includes ESIC hospitals for industrial employees, Command and Military Hospitals, General Hospitals, and last mile clinics in cities such as Lucknow, Chennai, Nagpur, Delhi, Ahmedabad, and Kolkata. In pilot research undertaken prior to the launch of this program, 2800+ patients were evaluated, and 35-40 percent of them were diagnosed with lung issues ranging from 10-12 years old to 85-90 years old.
Dr. Prashant Patel, Founder, CEO, Alveofit, said, “Alveofit-AstraZeneca collaboration is helping the basic respiratory disease diagnostics affordable and accessible at the last mile in public health infrastructure as well as through the corner clinics. These diseases disproportionately affect low-income population given the nature of their living and working conditions. This deployment was the need of the hour given the rising pollution and post COVID-19 world aiding the diagnosis of the respiratory diseases early in the cycle, so as to stop them from progressing ahead and help raise the standard of lives of the patients leading them to live a symptom-free life.”
AstraZeneca has been developing innovative methods to assist people in managing their own health. Insights from patients and caregivers from various communities have assisted the company in developing new practices and technologies that enable people to take an active role in their own health by utilizing tools such as digital sensors, integrated apps, connected devices, and artificial intelligence. AstraZeneca and Alveofit intend to expand this effort to tier-2 and tier-3 communities across India in order to make basic respiratory diagnosis and care available to everyone. Alveofit won the JANCare Innovation Challenge, which was conducted by BIRAC and NASSCOM CoE, an ISHIC partner.
Discussion about this post